Year-end Sale % OFF 
Abstract
The 5-y analysis of the Phase III COMBI-AD trial (NCT01682083) showed long-term RFS benefit with 12 months of adjuvant dabrafenib (dab) plus trametinib (tram) vs placebo (pbo) in patients with resected stage III BRAF V600E/K–mutant melanoma (5-y RFS rate, 52% vs 36%; hazard ratio, 0.51 [95% CI, 0.42-0.61]). A prior regression tree analysis (median follow-up in the dab + tram arm, 44 mo) evaluated 13 patient and clinical characteristics to identify treatment type (dab + tram vs pbo), disease stage, and age as predictive of long-term benefit.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
